Plus   Neg

Stock Alert: BioSig Down 10%; Acquires Anti-viral Agent That May Treat COVID-19

Shares of BioSig Technologies Inc. (BSGM) are currently down 10% on Wednesday morning.

The medical technology company announced that it acquired license for a broad-spectrum anti-viral agent that may treat COVID-19. The company did not disclose any financial details of the deal.

BioSig Technologies said its majority-owned subsidiary NeuroClear Technologies acquired the rights to develop a novel pharmaceutical to treat COVID-19.

The company said the anti-viral agent, Vicromax, in a preliminary internal review, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. In this analysis, Vicromax was added to a tissue culture assay for SARS-CO-2 coronavirus and an anti-viral effect was observed, which led to a reduction of over 90% of infectious viruses.

The company said it intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials.

The company aims to develop Vicromax and take it through clinical trials under a new NeuroClear subsidiary, ViralClear Pharmaceuticals, Inc.

BSGM is currently trading at $3.44, down $0.40 or 10.4%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT